Table 1. Baseline properties, electrocardiogram, angiographic findings, one-year mortality, and repeat revascularization rates of all cases.
| All patients (n = 152) | Non-severe CAD (n = 99) | Severe CAD (n = 53) | p value | |
| Age | 65 ± 12 | 64 ± 11 | 66 ± 13 | 0.685 |
| Gender (female), n (%) | 58 (38.2) | 32 (32.3) | 26 (49.1) | 0.043 |
| Diabetes mellitus, n (%) | 40 (26.3) | 23 (23.2) | 17 (32.1) | 0.238 |
| Hypertension, n (%) | 97 (63.8) | 63 (63.6) | 34 (64.2) | 0.950 |
| Smoking, n (%) | 65 (42.8) | 47 (47.5) | 18 (34.0) | 0.109 |
| Fasting blood glucose, mg/dl | 106 (95-127) | 106 (95-127) | 118 (93-127) | 0.754 |
| Creatinine, mg/dl | 0.9 (0.7-1) | 0.9 (0.7-1) | 1.0 (0.7-1.1) | 0.988 |
| Total cholesterol, mg/dl | 159 (139-194) | 161 (140-194) | 164 (141-194) | 0.515 |
| LDL-C, mg/dl | 102 (79-121) | 103 (78-120) | 104 (88-127) | 0.542 |
| HDL-C, mg/dl | 35 (29-40) | 35 (29-40) | 33 (28-40) | 0.481 |
| Triglyceride, mg/dl | 108 (79-158) | 104 (77-151) | 112 (95-165) | 0.179 |
| Hemoglobin, g/dl | 13.7 ± 1.9 | 13.8 ± 2.0 | 13.4 ± 1.5 | 0.257 |
| Troponin I, ng/ml | 1.1 (0.1-6.1) | 1.0 (0.1-6.5) | 1.5 (0.3-4.7) | 0.609 |
| Left ventricular ejection fraction, % | 55 (49-64) | 56 (50-64) | 54 (49-59) | 0.010 |
| Heart rate, bpm | 72 ± 13 | 71 ± 13 | 74 ± 13 | 0.212 |
| ST segment depression, n (%) | 9 (5.9) | 3 (3) | 6 (11.3) | 0.039 |
| ST elevation in aVR, n (%) | 18 (11.8) | 8 (8.1) | 10 (18.9) | 0.052 |
| T wave inversion, n (%) | 49 (32.2) | 36 (36.4) | 13 (24.5) | 0.137 |
| Q wave, n (%) | 49 (32.2) | 28 (28.3) | 21 (39.6) | 0.154 |
| Left ventricular hypertrophy, n (%) | 26 (17.1) | 12 (12.1) | 14 (26.4) | 0.026 |
| Prolonged JTc, n (%) | 43 (28.3) | 25 (25.3) | 18 (34) | 0.256 |
| QRS duration, n (%) | 0.418 | |||
| ≤ 80 ms | 11 (7.2) | 8 (8.1) | 3 (5.7) | |
| 81-110 ms | 80 (52.6) | 55 (55.6) | 25 (47.2) | |
| > 110 ms | 61 (40.1) | 36 (36.4) | 25 (47.2) | |
| Risk-based ECG score categories, n (%) | 0.013 | |||
| Low risk (0-1) | 49 (32.2) | 38 (38.4) | 11 (20.8) | |
| Moderate risk (2) | 55 (36.2) | 35 (35.4) | 20 (37.7) | |
| High risk (3-5) | 48 (31.6) | 26 (26.3) | 22 (41.5) | |
| High SYNTAX score, n (%) | 20 (43.5) | 9 (19.1) | 18 (30.5) | 0.040 |
| SYNTAX score | 15 (9-21) | 12 (8-16) | 25 (22-28) | < 0.001 |
| Three-vessel disease, n (%) | 20 (13.2) | 0 (0) | 20 (37.7) | < 0.001 |
| LMCA disease, n (%) | 13 (8.6) | 0 (0) | 13 (24.5) | < 0.001 |
| Chronic total occlusion, n (%) | 53 (34.9) | 20 (20.2) | 33 (62.3) | < 0.001 |
| Coronary artery calcification, n (%) | 34 (22.4) | 11 (11.1) | 23 (43.4) | < 0.001 |
| Coronary artery bifurcation lesions | 27 (17.8) | 11 (11.1) | 16 (30.2) | 0.003 |
| Coronary artery lesion length > 20 mm | 104 (68.4) | 64 (64.6) | 40 (75.5) | 0.171 |
| One-year mortality, n (%) | 9 (5.9) | 4 (4) | 5 (9.4) | 0.179 |
| Repeat revascularization, n (%) | 7 (4.6) | 4 (4) | 3 (5.7) | 0.650 |
CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LMCA, left main coronary artery; SYNTAX, the synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery.